Objectivity and Balance. The content or format of the activity or its related materials must promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. Presentations must give a balanced view of therapeutic options.
Objectivity and Balance. Provider will make every effort to ensure that data regarding the company’s products (or competing products) are objectively selected and presented, with favorable or unfavorable information and balance discussion of prevailing information on the product(s) and/or alternatives.
Objectivity and Balance. AKH will make every effort to ensure that data regarding the company’s products (or competing products) are objectively selected and presented, with favorable and unfavorable information and balanced discussion of prevailing information on the product(s) and/or alternative treatments.
Objectivity and Balance. ASAM will make every effort to ensure that data regarding products (or competing products) are objectively elected and presented, with favorable and unfavorable information and balanced discussion of prevailing information on the product(s) and/or alternative treatments.
Objectivity and Balance. CME Provider and Joint Provider will make every effort to ensure that all presentations give a balanced view of therapeutic options with meaningful disclosure of limitations on data, e.g., ongoing research, interim analysis, preliminary data, or unsupported opinion and ensure meaningful opportunities for questioning or scientific debate. CME Provider and Joint Provider will inform presenters that they are required to disclose when a product is considered off-label or investigational.
Objectivity and Balance a. The Grant Activity will be independent, non- promotional and free from commercial influence or bias.
Objectivity and Balance. CME Provider will make every effort to ensure that all presentations give a balanced view of therapeutic options with meaningful disclosure of limitations on data, e.g., ongoing research, interim analysis, preliminary data, or unsupported opinion and ensure meaningful opportunities for questioning or scientific debate. CME Provider will inform presenters that they are required to disclose when a product is considered off-label or investigational. RECEIPT FOR AND USE OF COMMERCIAL SUPPORT: CME Provider will, upon request, furnish Ineligible Company with documentation detailing the receipt and expenditure of the Commercial Support. CME Provider agrees that the commercial support will be used only for the support of the CME Meeting, and if requested, shall return to the Ineligible Company any funds that are not used for that purpose.
Objectivity and Balance. AUA will make every effort to ensure that data regarding the company’s products (or competing products) are objectively selected and presented, with favorable and unfavorable information and balanced discussion of prevailing information on the product(s) and/or alternative treatments.
Objectivity and Balance. Speaker agrees to make every effort to ensure that any product specific data are objectively selected and presented, with favorable and unfavorable information and he/she will present a balanced discussion.
Objectivity and Balance. 1. Orlando Health will make every effort to ensure that data regarding the Commercial Interest’s products are objectively selected and presented with favorable and unfavorable information and balanced discussion of prevailing information on the product based on scientific evidence.
